youtube_live
Q2 2026 earnings • released • Revenue miss -36.85%
See resultschevron_right
ALCLS:EPA
Cellectis SA
€2.63
arrow_downward
-3.80%(-0.10) 1D
Sep 11, 5:35:12 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALCLS...
Open
€2.72
High
€2.75
Low
€2.62
Mkt. cap
186.30M
Avg. vol.
126.86K
Volume
129.90K
52-wk high
€4.84
52-wk low
€2.03
EPS
-€0.56
Shares outstanding
72.09M
No. of employees
227
Open
€2.72
High
€2.75
Low
€2.62
Mkt. cap
186.30M
Avg. vol.
126.86K
Volume
129.90K
52-wk high
€4.84
52-wk low
€2.03
EPS
-€0.56
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
TipRanks
·
2 hours ago
Cellectis Plans September 14 Business Update Webcast for Global Investors
Stock Titan
·
2 hours ago
Cellectis (CLLS) plans Sept. 14 bilingual business update
Stock Titan
·
2 hours ago
Cellectis (CLLS) revenue tumbles but cash seen funding 12 months
Yahoo Finance Singapore
·
3 hours ago
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA